Calidi Biotherapeutics, Inc. (CLDI)

NYSEAMERICAN: CLDI · Real-Time Price · USD

1.640

+0.147 (9.85%)

At close: Jul 31, 2026, 4:00 PM EDT

1.700

+0.060 (3.66%)

Pre-market: Aug 3, 2026, 5:56 AM EDT

Calidi Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	6.63	5.6	9.59	1.95	0.37	1.06
Cash & Short-Term Investments	6.63	5.6	9.59	1.95	0.37	1.06
Cash Growth	-37.21%	-41.61%	392.10%	423.93%	-64.99%	-
Other Current Assets	0.72	0.66	0.64	2.35	0.41	0.42
Total Current Assets	7.35	6.26	10.23	4.3	0.79	1.48
Net Property, Plant & Equipment	2.1	2.46	3.8	5.34	1.09	-
Long-Term Investments	-	-	-	-	-	230
Other Long-Term Assets	0.14	0.14	0.15	0.37	0.73	0.28
Total Assets	9.59	8.86	14.18	10.02	2.6	231.77

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	0.9	0.02	0	2.88	2.27	0.06
Accrued Expenses	1.43	0.53	0.48	5.43	5.35	0.35
Short-Term Debt	-	-	-	-	1	-
Current Portion of Long-Term Debt	-	-	3.18	0.81	3.27	-
Current Portion of Leases	1.5	1.52	1.27	1.12	0.12	-
Other Current Liabilities	-	-	0.64	-	30.98	-
Total Current Liabilities	3.84	3.94	9.5	10.23	42.99	0.41
Long-Term Debt	0.6	0.6	0.6	2.06	-	-
Long-Term Leases	0.15	0.45	1.99	3.25	0.45	-
Other Long-Term Liabilities	0.07	0.12	0.13	2.71	-	16.04
Total Long-Term Liabilities	0.82	1.16	2.72	8.02	0.45	16.04
Total Liabilities	4.66	5.1	12.21	18.25	43.44	16.45

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	-	-	-	0	0	0
Additional Paid-in Capital	150.69	145.39	123.28	91.38	19.93	-
Accumulated Other Comprehensive Income	-0.02	-0.01	-0.03	-0.05	-0.01	-
Retained Earnings	-145.73	-141.62	-121.72	-99.57	-70.36	-14.69
Total Common Shareholders' Equity	4.93	3.76	1.53	-8.24	-50.44	-14.69
Minority Interest	-	-	0.43	-	9.6	230
Shareholders' Equity	4.94	3.76	1.97	-8.24	-40.84	215.32
Total Liabilities & Equity	9.59	8.86	14.18	10.02	2.6	231.77

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	2.26	2.56	7.04	7.24	4.84	0
Net Cash (Debt)	4.37	3.04	2.56	-5.29	-4.46	1.06
Net Cash Growth	-25.31%	18.83%	-	-	-	-
Net Cash Per Share	11.10	11.29	61.29	-	-	103.32
Book Value	4.93	3.76	1.53	-8.24	-50.44	-14.69
Book Value Per Share	12.52	13.98	36.80	-	-	-1427.93
Tangible Book Value	4.93	3.76	1.53	-8.24	-50.44	-14.69
Tangible Book Value Per Share	12.52	13.98	36.80	-	-	-1427.93

SEC Filings: 10-K · 10-Q